✦ LIBER ✦

1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Scribed by Tatum, H.; Thuluvath, P.; Lawitz, E.; Martorell, C.T.; Demicco, M.; Cohen, S.; Rustgi, V.; Ravendhran, N.; Ghalib, R.; Hanson, J.; Zamparo, J.; Yang, R.; Hughes, E.; Cooney, E.

Book ID: 123358122
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(12)61175-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1195 BMS-650032, AN NS3 INHIBITOR, IN CO

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Bronowicki, J.-P.; Pol, S.; Thuluvath, P.J.; Larrey, D.; Martorell, C.T.; Rustgi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

1096 ASUNAPREVIR (ASV; BMS-650032), AN N

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Bronowicki, J.-P.; Pol, S.; Thuluvath, P.; Larrey, D.; Martorell, C.T.; Rustgi, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Randomized Controlled Trial of Danoprevi

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

✍ Marcellin, Patrick; Cooper, Curtis; Balart, Luis; Larrey, Dominique; Box, Terry; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 517 KB

Peginterferon alfa-2a and peginterferon

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study

✍ Berak, Hanna; Laskus, Tomasz; Kołakowska-Rządzka, Anna; Wasilewski, Marek; Stańc 📂 Article 📅 2014 🏛 Versita 🌐 English ⚖ 276 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

✍ Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hac 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 182 KB